-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on BioNTech, Lowers Price Target to $125

Benzinga·11/04/2026 23:14:42
Listen to the news
UBS analyst David Dai maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $135 to $125.